|
|
Correlation Between Serum Parathyroid Hormone 25-Hydroxyvitamin D Bone Metabolism Markers and Bone Mineral Density in Patients with Postmenopausal Osteoporosis |
XIE Shuyong, et al |
Fuyang People's Hospital, Anhui Fuyang 236000, China |
|
|
Abstract Objective: To investigate the correlation between levels of serum parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D3] and bone metabolism markers and bone mineral density in patients with postmenopausal osteoporosis. Methods: 108 patients with postmenopausal osteoporosis admitted to the hospital between July 2019 and June 2021 were selected as observation group, and another 108 normal menopausal women undergoing physical examination during the same period were included in control group. The levels of PTH, 25(OH)D3 and bone metabolism markers were detected between observation group and control group, and their correlation with bone mineral density was analyzed. Results: Comparison of levels of PTH and 25(OH)D3 showed that compared with control group, there was no statistical significance in the level of PTH in observation group (P>0.05), and the level of 25(OH)D3 was lower (P<0.01). In terms of levels of bone metabolism markers in the two groups, the levels of N-terminal propeptide of type I procollagen, β-cross-linked C-terminal telopeptide of type I collagen, bone alkaline phosphatase, and osteocalcin were higher in observation group than those in control group (P<0.01). Comparison of bone mineral densities of different parts showed that the bone mineral densities of total hip bone, femoral neck and lumbar L1-4 in observation group were lower compared to control group (P<0.01). The bone mineral density of patients with postmenopausal osteoporosis was positively correlated with parathyroid hormone and 25-hydroxyvitamin D (P<0.01), and was negatively correlated with age, N-terminal propeptide of type I procollagen, β-cross-linked C-terminal telopeptide of type I collagen, bone alkaline phosphatase and osteocalcin (P<0.01). Conclusion: The bone mineral density in patients with postmenopausal osteoporosis is related to serum 25-hydroxyvitamin D and bone metabolism markers.
|
|
|
|
|
[1] 林依怀,王史潮,吕存贤.中医综合养生干预对绝经后骨密度低下女性骨密度和骨代谢标志物的影响[J].中华全科医学,2020,18(8):1373~1375,1408. [2] 邱伟,连星烨.唑来膦酸干预老年骨质疏松性股骨转子间骨折髋关节置换后患者骨密度、骨代谢标志物的2年随访[J].中国组织工程研究,2021,25(33):5265~5272. [3] 潘林雅,李功华,边平达,等.老年女性服用复方钙剂与骨代谢标志物和骨密度的关系[J].浙江临床医学,2018,20(2):208~209. [4] 黄长安,喻景弈.血清癌胚抗原相关细胞黏附分子1、骨标志物硬化蛋白、Ⅰ型前胶原氨基端延长肽及护骨素变化与绝经后骨质疏松病人骨密度变化的相关性[J].安徽医药,2020,24(9):1828~1831. [5] Kanis J,Pers Pective.The diagnosis of osteoporosis[J].Journal of Bone & Mineral Search,1994,9(8):1137~1141. [6] 韦丽红,张劼.中老年2型糖尿病患者25羟维生素D3与骨密度的相关性研究[J].广西医科大学学报,2018,35(6):849~852. [7] 查显友,周燕,周勇,等.首发精神分裂症患者骨代谢生化指标、25-羟维生素D3和甲状旁腺激素水平与骨密度的相关研究[J].中国卫生检验杂志,2020,30(14):1747~1749,1755. [8] 张鹏,罗伟,张冬梅,等.老年骨质疏松症不同中医证型中BMD、25(OH)D3及PTH的比较和相关性分折[J].四川中医,2020,38(4):81~83. [9] 赵敏.老年骨质疏松症患者25羟基维生素D3和骨代谢指标水平变化及其与骨密度的相关性分析[J].海军医学杂志,2020,41(6):721~723. [10] 王传珍,滕军燕,赵振江,等.补肾活血方联合骨化三醇治疗绝经后骨质疏松症对骨密度及骨代谢指标的影响[J].辽宁中医杂志,2020,47(9):60~62. [11] 李琪,陈先丹,牟芝群,等.绝经后2型糖尿病患者血清25(OH)D、LePtin与骨代谢的相关性[J].中国骨质疏松杂志,2018,24(12):1612~1616. [12] 黄靓,陆邦超.血清25羟维生素D、瘦素水平与女性绝经后2型糖尿病患者骨密度的关系[J].中国医药导报,2019,16(29):132~135. |
|
|
|